Abstract
Liposome-linear polyethyleneimine (PEI)-DNA nanocomplexes have shown to be effective non-viral gene delivery vectors. In the present study, we tried to improve the transfection efficiency of these nanocomplexes by liposome modification. For this purpose, the lipopolymer was prepared by the conjugation of hexylacrylate to the PEI. Liposomes comprising lipopolymer and DOTAP (1.2-DiOleoyl-3-Trimethyl Ammonium-Propane) were prepared and extruded through polycarbonate filters to obtain the desired size. The 2.5, 25 and 250 KDa molecular weights of linear PEI have been used in order to prepare modified liposome-PEI-DNA nanocomplexes. Three C/P ratios of each nancomplex were premixed. Size, zeta potential and the DNA condensation ability of these complexes were determined separately, and in the end, the transfection efficiency and cell cytotoxicity of prepared vectors were evaluated on Neuro2A cell line. Mean particle size of all of these nanocomplexes was lower than 220 nm with surface charge of 17.5 to 25.9 mV. The lipopolyplexes (comprising modified liposome:PEI:DNA), modified liposome (as lipoplex) and PEI 250KDa (as polyplex) showed the highest transfection efficacy. This activity was amplified by increase carrier to plasmid (C/P) ratio. In addition, the metabolic activity of prepared vectors was 80-100% for control group. In conclusion, the prepared lipopolyplexes showed high ability to enhance gene transfer.
Keywords: Gene delivery, Liposomes, Lipopolyplexes, Non-viral vector, Polyethyleneimine, Transfection efficiency.
Current Drug Delivery
Title:Preparation and in-vitro Transfection Efficiency Evaluation of Modified Cationic Liposome-polyethyleneimine-plasmid Nanocomplexes as a Novel Gene Carrier
Volume: 11 Issue: 5
Author(s): Asma Mahmoudi, Reza Kazemi Oskuee, Mohammad Ramezani and Bizhan Malaekeh-Nikoue
Affiliation:
Keywords: Gene delivery, Liposomes, Lipopolyplexes, Non-viral vector, Polyethyleneimine, Transfection efficiency.
Abstract: Liposome-linear polyethyleneimine (PEI)-DNA nanocomplexes have shown to be effective non-viral gene delivery vectors. In the present study, we tried to improve the transfection efficiency of these nanocomplexes by liposome modification. For this purpose, the lipopolymer was prepared by the conjugation of hexylacrylate to the PEI. Liposomes comprising lipopolymer and DOTAP (1.2-DiOleoyl-3-Trimethyl Ammonium-Propane) were prepared and extruded through polycarbonate filters to obtain the desired size. The 2.5, 25 and 250 KDa molecular weights of linear PEI have been used in order to prepare modified liposome-PEI-DNA nanocomplexes. Three C/P ratios of each nancomplex were premixed. Size, zeta potential and the DNA condensation ability of these complexes were determined separately, and in the end, the transfection efficiency and cell cytotoxicity of prepared vectors were evaluated on Neuro2A cell line. Mean particle size of all of these nanocomplexes was lower than 220 nm with surface charge of 17.5 to 25.9 mV. The lipopolyplexes (comprising modified liposome:PEI:DNA), modified liposome (as lipoplex) and PEI 250KDa (as polyplex) showed the highest transfection efficacy. This activity was amplified by increase carrier to plasmid (C/P) ratio. In addition, the metabolic activity of prepared vectors was 80-100% for control group. In conclusion, the prepared lipopolyplexes showed high ability to enhance gene transfer.
Export Options
About this article
Cite this article as:
Mahmoudi Asma, Oskuee Kazemi Reza, Ramezani Mohammad and Malaekeh-Nikoue Bizhan, Preparation and in-vitro Transfection Efficiency Evaluation of Modified Cationic Liposome-polyethyleneimine-plasmid Nanocomplexes as a Novel Gene Carrier, Current Drug Delivery 2014; 11 (5) . https://dx.doi.org/10.2174/1567201811666140616160237
DOI https://dx.doi.org/10.2174/1567201811666140616160237 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Current Drug Targets The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Improving the Stability of Aptamers by Chemical Modification
Current Medicinal Chemistry Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Ionic Liquids, Microextraction Methods and Capillary Electrophoresis in Biomedical Research
Current Pharmaceutical Analysis Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Moving Beyond Tyrosine Hydroxylase to Define Dopaminergic Neurons for Use in Cell Replacement Therapies for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy